BIOGEN INC.
For the period ended Jun 30, 2026. Filed Jul 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
ISSUER PURCHASES OF EQUITY SECURITIES
The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the second quarter of 2026:
| Period | Total Number ofShares Purchased(#) | Average PricePaid per Share($) | Total Number ofShares Purchasedas Part of PubliclyAnnounced Programs(#) | Approximate Dollar Valueof Shares That May Yet Be Purchased UnderOur Programs($ in millions) |
|---|---|---|---|---|
| April 1, 2026 - April 30, 2026 | — | $— | — | $2,050.0 |
| May 1, 2026 - May 31, 2026 | — | $— | — | $2,050.0 |
| June 1, 2026 - June 30, 2026 | — | $— | — | $2,050.0 |
| Total(1) | — | $— | ||
(1)There were no share repurchases during the second quarter of 2026.
In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three months ended June 30, 2026 and 2025. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of June 30, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.